CP-96021

CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma[1].

Product Specifications

CAS Number

[139401-43-7]

UNSPSC

12352005

Target

Leukotriene Receptor; Platelet-activating Factor Receptor (PAFR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cp-96021.html

Purity

98.04

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

CC1=NC2=CN=CC=C2N1C3=CC=C(C=C3)OCC4=CC(/C=C/C5=NC6=CC(F)=CC=C6S5)=CC=C4

Molecular Formula

C29H21FN4OS

Molecular Weight

492.57

References & Citations

[1]Marfat A, et al. The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4) /platelet activating factor (PAF) receptor antagonists[J]. Bioorganic & Medicinal Chemistry Letters, 1995, 5 (13) : 1377-1382.